# CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

> **NCT04162340** · PHASE1 · UNKNOWN · sponsor: **iCell Gene Therapeutics** · enrollment: 12 (estimated)

## Conditions studied

- T Cell Lymphoma in Relapse
- Refractory T-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** CD4 CAR T cells

## Key facts

- **NCT ID:** NCT04162340
- **Lead sponsor:** iCell Gene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-11
- **Primary completion:** 2021-10
- **Final completion:** 2021-10
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2021-05-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04162340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04162340, "CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04162340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*